• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CVRx Inc.

    2/18/25 7:56:26 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care
    Get the next $CVRX alert in real time by email
    S-8 1 tm256776d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on February 18, 2025

    Registration No. 333-________

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    CVRx, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 41-1983744
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

     

    9201 West Broadway Avenue, Suite 650

    Minneapolis, MN 55445

    (Address of Principal Executive Offices, including zip code)

     

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full title of the Plans)

     

    Kevin Hykes

    President and Chief Executive Officer

    CVRx, Inc.

    9201 West Broadway Avenue, Suite 650

    Minneapolis, MN 55445

    (Name and address of agent for service)

     

    (763) 416-2840

    (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer  ¨   Accelerated filer ¨
    Non-accelerated filer  x   Smaller reporting company x
          Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 1,519,480 shares of Common Stock, par value $0.01 per share, of CVRx, Inc. (the “Registrant”), issuable under the following employee benefit plans for which Registration Statements on Form S-8 (File Nos. 333-257616, 333-262901, 333-269696, and 333-276984) (the “Prior Registration Statements”) are effective: (i) the 2021 Equity Incentive Plan (the “2021 Plan”) which, as a result of an automatic annual increase provision therein, added 1,266,234 shares of Common Stock, and (ii) the Employee Stock Purchase Plan (the “ESPP”), which, as a result of the operation of an automatic annual increase provision therein, added 253,246 shares of Common Stock.

     

    This Registration Statement is submitted in accordance with General Instruction E to Form S-8.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS
    ON FORM S-8

     

    The contents of the Registrant’s Registration Statements on Form S-8 (File Nos. 333-257616, 333-262901, 333-269696, and 333-276984), relating to the 2021 Plan and the ESPP are incorporated herein by reference.

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
    4.1   Restated Certificate of Incorporation of CVRx, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 7, 2024).
    4.2   Amended and Restated Bylaws of CVRx, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on July 7, 2021).
    5.1   Opinion of Faegre Drinker Biddle & Reath LLP.
    10.1   2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-8 filed on July 1, 2021).
    10.2   Form of Stock Option Agreement (Employees/Officers) pursuant to 2001 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-8 filed on July 1, 2021).
    10.3   Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant’s Registration Statement on Form S-8 filed on July 1, 2021).
    10.4   Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K filed on February 22, 2022).
    23.1   Consent of Independent Registered Public Accounting Firm.
    23.2   Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1).
    24.1   Power of Attorney.
    107   Filing Fee Table.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Minneapolis, State of Minnesota, on February 18, 2025.

     

      CVRx, INC.
       
      By: /s/ Kevin Hykes
        Kevin Hykes
        President and Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated:

     

    Signature   Title
         
    /s/ Kevin Hykes   President and Chief Executive Officer
    Kevin Hykes   (Principal Executive Officer)
         
    /s/ Jared Oasheim   Chief Financial Officer
    Jared Oasheim   (Principal Financial and Accounting Officer)
         
    *   Director
    Kevin Ballinger    
         
    *   Director
    Mitch Hill    
         
    *   Director
    Mudit Jain    
         
    *   Director
    Kirk Nielsen    
         
    *   Director
    Martha Shadan    
         
    *   Director
    Joseph Slattery    

     

    * Jared Oasheim, by signing his name hereto on the 18th day of February, 2025, does hereby sign this document pursuant to powers of attorney duly executed by the directors named, filed with the Securities and Exchange Commission on behalf of such directors, all in the capacities and on the date stated.

     

     

     

    Get the next $CVRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVRX

    DatePrice TargetRatingAnalyst
    5/9/2025$7.00Neutral → Underweight
    Analyst
    1/14/2025Mkt Perform → Outperform
    William Blair
    9/10/2024$14.00Overweight
    Cantor Fitzgerald
    7/11/2024$18.00 → $12.00Buy
    Lake Street
    5/1/2024$30.00 → $23.00Buy
    Craig Hallum
    5/1/2024Outperform → Mkt Perform
    William Blair
    5/1/2024$36.00 → $13.00Overweight → Neutral
    JP Morgan
    1/31/2023$20.00Buy
    Lake Street
    More analyst ratings

    $CVRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Large owner Johnson & Johnson sold $224,040 worth of shares (22,337 units at $10.03) (SEC Form 4)

    4/A - CVRx, Inc. (0001235912) (Issuer)

    1/8/26 4:05:54 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Large owner Johnson & Johnson sold $63,560 worth of shares (6,337 units at $10.03) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    12/1/25 4:07:15 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Large owner Johnson & Johnson sold $10,000 worth of shares (1,000 units at $10.00) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    11/14/25 3:07:10 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CVRx Inc.

    SCHEDULE 13G/A - CVRx, Inc. (0001235912) (Subject)

    1/12/26 7:51:15 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - CVRx, Inc. (0001235912) (Filer)

    1/12/26 8:57:19 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by CVRx Inc.

    424B5 - CVRx, Inc. (0001235912) (Filer)

    1/12/26 8:45:53 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVRx, Inc. downgraded by Analyst with a new price target

    Analyst downgraded CVRx, Inc. from Neutral to Underweight and set a new price target of $7.00

    5/9/25 8:41:10 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx, Inc. upgraded by William Blair

    William Blair upgraded CVRx, Inc. from Mkt Perform to Outperform

    1/14/25 7:51:14 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on CVRx, Inc. with a new price target

    Cantor Fitzgerald initiated coverage of CVRx, Inc. with a rating of Overweight and set a new price target of $14.00

    9/10/24 7:46:21 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

    MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim™ in a significantly expanded heart failure population. Barostim™ is an implantable device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signaling, rebalancing the autonomic nervous system, and improving heart failure symptoms.

    1/22/26 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

    Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18%Category I CPT codes and the related favorable physician fee payment levels took effect on Jan. 1, 2026FDA approved the BENEFIT-HF trial design in November and the Company has since applied to CMS for coverage for the trialDebt facility amended to extend maturity date to 2031 and to increase the facility from the $50 million of term loans already drawn by an additional $50 million, of which $1

    1/12/26 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nielsen Kirk G. bought $59,795 worth of shares (10,966 units at $5.45) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/19/25 6:46:37 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Nielsen Kirk G. bought $977,346 worth of shares (187,813 units at $5.20) (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/14/25 5:27:07 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Director Jain Mudit K. bought $7,775 worth of shares (1,650 units at $4.71), increasing direct ownership by 49% to 5,050 units (SEC Form 4)

    4 - CVRx, Inc. (0001235912) (Issuer)

    5/13/25 7:12:40 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Leadership Updates

    Live Leadership Updates

    View All

    CVRx Announces Appointment of Robert Allen John as Chief Revenue Officer

    MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and establishing Barostim as standard of care in the United States. "We are thrilled to welcome Robert to the CVRx executive team as we continue to expand the adoption of Barostim therapy," said Kevin Hykes, President and CEO of CVRx. "Robert is well-known and respected within the heart failure community and

    6/25/24 6:50:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

    Appointment effective February 12 following Nadim Yared's retirement Hykes currently serves as Augmedics' President and CEO, and has served on CVRx's Board of Directors since 2022 MINNEAPOLIS, Jan. 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company's new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company's Board of Directors. Yared will retire from the Company and resign his Board seat concurrent with Hykes' appointment and has agreed to consult with the Company to ensure a seamless transition. Hykes is an accomplishe

    1/31/24 8:00:00 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Appoints Industry Veteran Kevin Hykes to Board of Directors

    MINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022. "We are excited to welcome an executive with the depth of expertise of Kevin Hykes to our Board of Directors," said John Nehra, lead independent director of CVRx. "His commercial experience in accelerating the growth of novel interventional therapies and his executive acumen will prove an invaluable resource as we continue to build our b

    12/20/22 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Financials

    Live finance-specific insights

    View All

    CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

    MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2025 financial and operating results after market close on Thursday, Feb. 12, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone

    1/29/26 4:10:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx Reports Third Quarter 2025 Financial and Operating Results

    MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2025. Recent Highlights Total revenue for the third quarter 2025 was $14.7 million, an increase of 10% over the prior year quarterU.S. revenue for the third quarter of 2025 was $13.5 million, an increase of 10% over the prior year quarterActive implanting centers in the U.S. grew to 250, an increase of 20% since September 30, 2024CMS published the final ru

    11/5/25 4:05:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

    MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2025 financial and operating results after market close on Wednesday, Nov. 5, 2025. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.A live webcast of the investor conference call will be available online at the investor relations page of the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, p

    10/22/25 4:30:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    $CVRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVRx Inc.

    SC 13D/A - CVRx, Inc. (0001235912) (Subject)

    11/7/24 9:10:51 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CVRx Inc.

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    11/1/24 11:05:15 AM ET
    $CVRX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by CVRx Inc. (Amendment)

    SC 13G/A - CVRx, Inc. (0001235912) (Subject)

    2/6/24 7:56:00 PM ET
    $CVRX
    Medical/Dental Instruments
    Health Care